<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728971</url>
  </required_header>
  <id_info>
    <org_study_id>SHLTQC-4</org_study_id>
    <nct_id>NCT04728971</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation</brief_title>
  <official_title>To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical success rate of micafungin in preventing invasive mycosis after&#xD;
      liver transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-transplant infections</measure>
    <time_frame>90 days</time_frame>
    <description>Frequency of clinically or microbiologically documented infection after transplantation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Micafungin Preventing Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Others Preventing Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micafungin Sodium 50 MG Injection</intervention_name>
    <description>Give Micafungin 150 mg/d within 24 hours after liver transplantation.</description>
    <arm_group_label>Micafungin Preventing Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caspofungin Acetate</intervention_name>
    <description>Give Caspofungin 35 mg/d lasts 1 week after liver transplantation.</description>
    <arm_group_label>Others Preventing Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign the informed consent form voluntarily;&#xD;
&#xD;
          2. Liver transplant patients with 1 high-risk factor; A. Transplant again; B. Fulminant&#xD;
             liver failure; C. Renal failure requires alternative treatment (defined as creatinine&#xD;
             clearance ≤40 ml/min); D. ICU duration before liver transplantation≥48h; E. Have&#xD;
             received abdominal surgery within one month before liver transplantation or; F. Common&#xD;
             bile duct jejunostomy (except for children); G. Excessive blood transfusion (blood&#xD;
             transfusion exceeds 2000mL); H. The donor's ICU hospital stay exceeds 5 days; I.&#xD;
             Positive sputum and blood culture of the donor J. The donor has evidence of lung or&#xD;
             bloodstream infection (pulmonary infection is evaluated according to the diagnostic&#xD;
             criteria and treatment principles (draft) of invasive lung fungal infection, and&#xD;
             bloodstream infection is evaluated according to invasive fungal disease of patients&#xD;
             with hematopathy/malignant tumor Diagnostic criteria and treatment principles (fifth&#xD;
             revised edition) for evaluation) K. 60 years old ≤ age ≤ 65 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have used other investigational drugs or are participating in other clinical trials&#xD;
             within 4 weeks before enrollment;&#xD;
&#xD;
          2. Currently combined with any kind of fungal infection;&#xD;
&#xD;
          3. Allergic to study drugs;&#xD;
&#xD;
          4. Joint transplantation;&#xD;
&#xD;
          5. Women who are pregnant, preparing to become pregnant or breast-feeding;&#xD;
&#xD;
          6. The investigator thinks that it is not suitable to use the test drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Lin Zhong</investigator_full_name>
    <investigator_title>Director of Hepatobiliary and Pancreatic Surgery</investigator_title>
  </responsible_party>
  <keyword>Micafungin</keyword>
  <keyword>Invasive Mycosis</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Micafungin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

